<DOC>
	<DOCNO>NCT00262834</DOCNO>
	<brief_summary>This phase II trial study well vorinostat work treat woman undergo surgery newly diagnose stage I , stage II , stage III breast cancer . Vorinostat may stop growth tumor cell block enzymes need cell growth . Giving vorinostat surgery may shrink tumor remove .</brief_summary>
	<brief_title>Vorinostat Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I , Stage II , Stage III Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . Determine safety tolerability vorinostat woman undergo surgery newly diagnose stage I-III breast cancer . OULINE : This multicenter , pilot study . Patients receive oral vorinostat twice daily day -3 0 . Approximately 2 hour final dose vorinostat , patient undergo surgical resection tumor day 0 . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>No prior concurrent hormonal therapy breast cancer Histologically confirm breast cancer , stage IIII disease , schedule undergo definitive surgery primary treatment ( e.g. , preoperative/neoadjuvant systemic treatment ) breast cancer ECOG 02 OR Karnofsky 60100 % Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin normal AST ALT ≤ 2.5 time upper limit normal PT ≤ 14 second Creatinine normal No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No ongoing active infection No psychiatric illness social situation would preclude study compliance No uncontrolled intercurrent illness No history allergic reaction attribute compound similar chemical biologic composition vorinostat At least 30 day since prior hormone replacement therapy ( e.g. , estrogen and/or progestin ) Concurrent vaginal hormone preparation ( e.g. , vagifem estring ) allow No concurrent birth control pills No prior radiotherapy ipsilateral breast No prior concurrent radiotherapy breast cancer No prior concurrent novel therapy breast cancer At least 14 day since prior valproic acid another histone deacetylase inhibitor No concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient No concurrent therapy cancer WBC ≥ 3,000/mm^3</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>